Short Interest in Aspira Women’s Health Inc. (NASDAQ:AWH) Grows By 10.9%

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 439,200 shares, a growth of 10.9% from the January 15th total of 396,200 shares. Currently, 3.6% of the shares of the company are sold short. Based on an average trading volume of 97,900 shares, the short-interest ratio is currently 4.5 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. lifted its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 33.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 316,294 shares of the company’s stock after purchasing an additional 79,898 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $256,000 as of its most recent filing with the Securities and Exchange Commission. 12.19% of the stock is currently owned by hedge funds and other institutional investors.

Aspira Women’s Health Price Performance

Shares of Aspira Women’s Health stock traded down $0.04 during trading on Friday, hitting $0.24. 907,741 shares of the company’s stock traded hands, compared to its average volume of 106,812. The firm’s fifty day moving average price is $0.57 and its 200 day moving average price is $0.80. Aspira Women’s Health has a twelve month low of $0.20 and a twelve month high of $5.00. The company has a market cap of $4.00 million, a PE ratio of -0.20 and a beta of 1.38.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Aspira Women’s Health in a research note on Sunday, January 12th. They set a “hold” rating on the stock.

Aspira Women’s Health Company Profile

Aspira Women’s Health, Inc engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.